The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 8, 2000.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 00–14945 Filed 6–12–00; 8:45 am]

BILLING CODE 4163–18–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

Name: Advisory Committee on Immunization Practices (ACIP).

Times and Dates: 8:30 a.m.–6:30 p.m., June 21, 2000. 8 a.m.–4:30 p.m., June 22, 2000.

Place: Four Points Hotel by Sheraton, 1850 Cotillion Drive, Atlanta, Georgia 30338.

Status: Open to the public, limited only by the space available.

Purpose: The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. § 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

Matters To Be Discussed: The agenda will include a discussion on the ACIP policies and procedures; ACIP recommendations for the pneumococcal conjugate vaccine; vaccine additive: aluminum update; vaccine additive: thimerosal; vaccines and autism; bioterrorism working group; general recommendations; anaphylaxis after MMR due to gelatin; progress report on vaccine identification standards initiative; status of high-speed needle-free jet injectors for mass vaccination campaigns; update on Geneva meeting on rotavirus vaccination; Vaccines for Children program update; adult working group: pneumococcal polysaccharide update; CDC/FDA report on two dose schedule for hepatitis B for adolescent; update on influenza vaccine supply; Global Alliance for Vaccines and Immunization: progress in supporting global immunization programs and introduction of new vaccines; Nabi an update from the Food and Drug Administration; update from the National Center for Infectious Diseases; update from the National Immunization Program; update from the Vaccine Injury Compensation Program; update from the National Vaccine Program. Other matters of relevance among the committee's objectives may be discussed.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Gloria A. Kovach, Program Analyst, Epidemiology and Surveillance Division, National Immunization Program, CDC, 1600 Clifton Road, NE, m/s E61, Atlanta, Georgia 30333. Telephone 404/639–8096.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: June 8, 2000.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 00–14944 Filed 6–12–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 92N–0412]

Rajaram K. Matkari; Conviction Reversal; Final Order Terminating Debarment

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is issuing an order, under the Federal Food, Drug, and Cosmetic Act (the act), terminating the debarment of Rajaram K. Matkari, 1304 Riverglen Way, Berthoud, CO 80513. FDA is issuing this order because the U.S. District Court for the District of Maryland issued a Writ of Error Coram Nobis, reversing Mr. Matkari's conviction and Mr. Matkari applied for termination of his debarment on this basis.

EFFECTIVE DATE: June 13, 2000.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Comments are to be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Leanne Cusumano, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of October 20, 1993 (58 FR 54156), Rajaram K. Matkari was permanently debarred from providing services in any capacity to a person with an approved or pending drug product application (sections 306(c)(1)(B) and (c)(2)(A)(ii) and 201(dd) of the act (21 U.S.C. 335a(c)(1)(B) and (c)(2)(A)(ii) and 21 U.S.C. 321(dd)). The debarment was based on FDA's finding that Mr. Matkari was convicted of a felony under Federal law for conduct relating to the development or approval of a drug product, or otherwise relating to the regulation of a drug product (section 306(a)(2)(A) and (a)(2)(B) of the act). Mr. Matkari, the former Vice President for Regulatory Affairs and Product Development of Pharmaceutical Basics, Inc. (PBI), pled guilty to and was sentenced on July 28, 1989, for giving an unlawful gratuity, a felony offense under 18 U.S.C. 201(c)(1)(A). The basis for this conviction was Mr. Matkari's payment of approximately $2,000 to an FDA chemistry review branch chief who was responsible for supervising the chemists who reviewed PBI's applications to determine whether those applications met certain statutory standards for approval.

On February 22, 2000, the U.S. District Court for the District of Maryland issued an order granting Mr. Matkari's petition for a Writ of Error Coram Nobis in his criminal case. A copy of the court's order is available in Docket No. 92N–0412. By this order, the court reversed Mr. Matkari's conviction. On April 18, 2000, Mr. Matkari petitioned for termination of debarment under section 306(d)(3)(B)(i) of the act, as amended by the Generic Drug Enforcement Act. Section 306(d)(3)(B)(i) of the act states that ''If the conviction which served as the basis for the debarment of an individual under subsection (a)(2) * * * is reversed, the Secretary shall withdraw the order of debarment.''

Accordingly, the Senior Associate Commissioner for Policy, Planning, and Legislation, under section 306(d)(3)(B)(i) of the act and under authority delegated to him (21 CFR 5.20), is issuing this order withdrawing the order of permanent debarment of Rajaram K. Matkari, thereby allowing him to provide services in any capacity to a person with an approved or pending drug product application. Rajaram K. Matkari's debarment is terminated